.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,166,046

« Back to Dashboard

Summary for Patent: 6,166,046

Title: Combination of atovaquone with proguanil for the treatment of protozoal infections
Abstract:The invention relates to combinations of atovaquone and proguanil, their use in the treatment and prophylaxis of parasitic infections such as protozoal parasitic infections, e.g., malaria and toxoplasmosis, and infections caused by P. carinii and their use in the manufacture of medicaments for the treatment and/or prophylaxis of such infections. The combinations can conveniently be administered in a single pharmaceutical formulation. Preferably, atovaquone and proguanil are administered in a potentiating ratio so that they act in synergy.
Inventor(s): Gutteridge; Winston Edward (Beckenham, GB), Hutchinson; David Brian Ashton (Beckenham, GB), Latter; Victoria Susan (Beckenham, GB), Pudney; Mary (Beckenham, GB)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:09/409,871
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 22nd percentile
Forward Citations: 1st percentile

No matches for this query

Foreign Priority and PCT Information for Patent: 6,166,046

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9224739Nov 26, 1992

International Patent Family for Patent: 6,166,046

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Hungary225918<disabled in preview>
HungaryT71346<disabled in preview>
Hungary9501537<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc